Dr. Christian Steidl receives AstraZeneca and Leukemia & Lymphoma Society Grant

Dr. Christian Steidl, senior scientist and Executive Director, Research at BC Cancer, is the recipient of a 2025 Operating Grant in Blood Cancer, co-funded by AstraZeneca Canada and the Leukemia & Lymphoma Society of Canada.

The research is dedicated to developing innovative tools for precise and efficient gene editing in B-cell lymphomas. By targeting the underlying genetic causes of cancer, this work paves the way for novel treatment strategies and opens new possibilities for patients living with B-cell lymphoma.

Dr. Ryan Morin receives Canadian Cancer Society Bernard and Francine Dorval Prize

Dr. Ryan Morin (Centre for Lymphoid Cancer) is the co-recipient of the Canadian Cancer Society (CCS) Bernard and Francine Dorval Prize. 

Dr. Morin is a national and international leader in his field of studying how changes to our genes lead to cancer. He has conducted cutting-edge research that has directly helped doctors understand, diagnose and better treat lymphomas. 

Study reveals cause for different outcomes for patients that experience early and late relapse of diffuse large B-cell lymphoma

A recent study conducted by TFRI-funded researchers at BC Cancer sheds light on the cause behind the different outcomes of patients with diffuse large B cell lymphoma (DLBCL) who experienced a relapse in their disease. The study confirmed that patients whose cancer relapses shortly after treatment typically have poor responses to additional chemotherapy-based treatment. However, when the relapse occurs more than two years from the time of diagnosis, the outcomes to chemotherapy are significantly better.

Back to top